844 related articles for article (PubMed ID: 26321400)
21. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System.
Godfrey H; Jedlowski P; Thiede R
Australas J Dermatol; 2024 May; 65(3):243-253. PubMed ID: 38572842
[TBL] [Abstract][Full Text] [Related]
22. Genotype-phenotype association between HLA and carbamazepine-induced hypersensitivity reactions: strength and clinical correlations.
Hsiao YH; Hui RC; Wu T; Chang WC; Hsih MS; Yang CH; Ho HC; Chang YG; Chen MJ; Lin JY; Chen DP; Chang PY; Wu TL; Hung SI; Chung WH
J Dermatol Sci; 2014 Feb; 73(2):101-9. PubMed ID: 24268988
[TBL] [Abstract][Full Text] [Related]
23. Stevens-Johnson syndrome and toxic epidermal necrolysis-challenges of recognition and management.
Sane SP; Bhatt AD
J Assoc Physicians India; 2000 Oct; 48(10):999-1003. PubMed ID: 11200928
[TBL] [Abstract][Full Text] [Related]
24. Recognition and Management of Severe Cutaneous Adverse Drug Reactions (Including Drug Reaction with Eosinophilia and Systemic Symptoms, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis).
Owen CE; Jones JM
Med Clin North Am; 2021 Jul; 105(4):577-597. PubMed ID: 34059239
[TBL] [Abstract][Full Text] [Related]
25. Severe cutaneous adverse reactions related to systemic antibiotics.
Lin YF; Yang CH; Sindy H; Lin JY; Rosaline Hui CY; Tsai YC; Wu TS; Huang CT; Kao KC; Hu HC; Chiu CH; Hung SI; Chung WH
Clin Infect Dis; 2014 May; 58(10):1377-85. PubMed ID: 24599767
[TBL] [Abstract][Full Text] [Related]
26. Identification of thymus and activation-regulated chemokine (TARC/CCL17) as a potential marker for early indication of disease and prediction of disease activity in drug-induced hypersensitivity syndrome (DIHS)/drug rash with eosinophilia and systemic symptoms (DRESS).
Ogawa K; Morito H; Hasegawa A; Daikoku N; Miyagawa F; Okazaki A; Fukumoto T; Kobayashi N; Kasai T; Watanabe H; Sueki H; Iijima M; Tohyama M; Hashimoto K; Asada H
J Dermatol Sci; 2013 Jan; 69(1):38-43. PubMed ID: 23141052
[TBL] [Abstract][Full Text] [Related]
27. Treatments for Severe Cutaneous Adverse Reactions.
Cho YT; Chu CY
J Immunol Res; 2017; 2017():1503709. PubMed ID: 29445753
[TBL] [Abstract][Full Text] [Related]
28. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions.
Lee T; Lee YS; Yoon SY; Kim S; Bae YJ; Kwon HS; Cho YS; Moon HB; Kim TB
J Am Acad Dermatol; 2013 Sep; 69(3):407-15. PubMed ID: 23632341
[TBL] [Abstract][Full Text] [Related]
29. Stevens Johnson syndrome-Toxic Epidermal Necrolysis Overlap induced by sulfasalazine treatment: a case report.
Zizi N; Elmrahi A; Dikhaye S; Fihmi N; Alami Z
Tunis Med; 2015 Jul; 93(7):413-5. PubMed ID: 26757493
[TBL] [Abstract][Full Text] [Related]
30. [Severe skin reactions due to new medications].
Mockenhaupt M; Paulmann M
Hautarzt; 2018 Apr; 69(4):278-289. PubMed ID: 29568997
[TBL] [Abstract][Full Text] [Related]
31. Elevated serum osteopontin levels in patients with severe cutaneous adverse drug reactions.
Suzuki M; Koshikawa S; Watanabe H; Inomata N; Yamaguchi Y; Aihara M; Sueki H
J Dermatol; 2023 Apr; 50(4):536-540. PubMed ID: 36540013
[TBL] [Abstract][Full Text] [Related]
32. Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.
Pavlos R; Mallal S; Ostrov D; Pompeu Y; Phillips E
J Allergy Clin Immunol Pract; 2014; 2(1):21-33. PubMed ID: 24565765
[TBL] [Abstract][Full Text] [Related]
33. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
34. Paracetamol (Acetaminophen)-associated SJS, TEN, AGEP, and DRESS Syndromes - A Narrative Review.
Pakkir Maideen NM; Barakat IR; Jumale AH
Curr Drug Saf; 2024; 19(2):218-223. PubMed ID: 37151075
[TBL] [Abstract][Full Text] [Related]
35. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
36. [Stevens-Johnson syndrome and toxic epidermal necrolysis: retrospective study of 185 cases in Abidjan (Côte d'Ivoire)].
Kourouma S; Sangaré A; Kaloga M; Kouassi I; Ecra E; Gbery I; Ahogo C; Kouassi A; Kassi K; Camara B
Med Sante Trop; 2014; 24(1):94-8. PubMed ID: 24736218
[TBL] [Abstract][Full Text] [Related]
37. A 10-years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia.
Loo CH; Tan WC; Khor YH; Chan LC
Med J Malaysia; 2018 Apr; 73(2):73-77. PubMed ID: 29703869
[TBL] [Abstract][Full Text] [Related]
38. Severe cutaneous adverse reactions in a local hospital setting: a 5-year retrospective study.
Su P; Aw CW
Int J Dermatol; 2014 Nov; 53(11):1339-45. PubMed ID: 25070588
[TBL] [Abstract][Full Text] [Related]
39. Drug reaction with eosinophilia and systemic symptoms with features resembling Stevens-Johnson syndrome/toxic epidermal necrolysis related to apalutamide.
Hsu YO; Hsieh TS; Huang PW; Chu CY
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):e246-e248. PubMed ID: 36223304
[No Abstract] [Full Text] [Related]
40. Febuxostat (Adenuric). Toxic epidermal necrolysis and severe hypersensitivity reactions added to the EU SPC.
Prescrire Int; 2015 Jun; 24(161):153. PubMed ID: 26436167
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
